Ozempic maker to cut thousands of jobs

Novo Nordisk, the manufacturer of Ozempic and Wegovy, announced plans to cut approximately 9,000 global jobs from its 78,400-person workforce to streamline operations and reallocate resources. This strategic move is a direct response to increasing competition in the obesity market, notably from Eli Lilly's Zepbound and Mounjaro, and the impact of compounding pharmacies, which have led to market share erosion and organizational complexity. The company aims to foster a more performance-based culture and prioritize investment in its core diabetes and obesity therapy areas, including R&D and manufacturing scale-up, to maintain leadership in an evolving, consumer-driven landscape.

Analysis

Novo Nordisk is undertaking a significant strategic restructuring, eliminating approximately 9,000 positions, or about 11.5% of its global workforce, to streamline operations and combat increasing competitive pressures. This defensive move is a direct acknowledgment of a "recent slowdown in growth" and market share erosion within the lucrative obesity drug market. The primary competitive threat cited is Eli Lilly, which has aggressively gained ground with its Zepbound and Mounjaro drugs, contributing to its $10.4 billion in second-quarter revenue. Further pressure stems from alternative products by compounding pharmacies that are impacting Novo Nordisk's profitability. The company's actions, including recent price cuts on Wegovy, signal a pivot from rapid expansion, which created "greater organizational complexity and higher costs," to a more focused, performance-driven culture. By reallocating resources from the eliminated roles, Novo Nordisk aims to bolster investment in science, commercial capabilities, and manufacturing to defend its position in a market that CEO Mike Doustdar describes as increasingly "competitive and consumer-driven."

Key Decisions for Investors

• Investors in Novo Nordisk should view this restructuring as a necessary defensive action; monitor subsequent earnings for evidence that the firm can stabilize market share and that operational efficiencies are countering the acknowledged growth slowdown.
• This development serves as a bullish indicator for Eli Lilly, as it validates the success of its competitive strategy with Zepbound and Mounjaro and suggests its market share momentum is directly impacting its primary rival.
• The explicit mention of price competition and the influence of compounding pharmacies indicates the obesity drug market is maturing, suggesting investors should temper long-term margin expectations for the sector as a whole.